- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01827228
Transmission Reduction Intervention Project (TRIP)
Preventing HIV Transmission by Recently-Infected Drug Users
Half or more of HIV transmission events may occur within the period of high infectivity (and often high risk behavior) that can last 11 months or more after a person is initially infected. Unfortunately, neither test-and-treat intervention methods nor Acute HIV Infection projects have found effective ways to intervene against transmission during this risky "recent infection" period. The investigators seek to develop effective intervention techniques against HIV transmission during the recent infection period using a combination of injection-, sexual- and social-network-based contact tracing methods; community alerts in the networks and venues of recent infectees; and the logic of going "up" and "down" infection chains.
The investigators first Aim is to develop and evaluate ways to locate "seeds," defined as drug users and other people who have recently been infected. The investigators second Aim targets members of seeds' networks and people who attend their venues. The investigators will test them for acute and for recent infection, and alert them to the probability that their networks contain highly-infectious members so they should reduce their risk and transmission behaviors for the next several months to minimize their chances of getting infected. This may also reduce transmission by untested people with recent infection. Community, network and venue education about the need and value of supporting those with recent infection should reduce stigma. The investigators third Aim is to reduce HIV transmission and to develop new ways to evaluate "prevention for positives" generally as well as The investigators own success in reducing transmission.
The investigators will do this using a combination of follow-up interviews and testing, including of viral loads; phylogenetic techniques; and discrete event simulation modeling to assess The investigators effectiveness.
Study Overview
Status
Conditions
Detailed Description
TRIP Design This is an exploratory research project. It aims to develop the TRIP model in preparation for a phase 3 clinical trial with random assignment of geographic areas to intervention versus control conditions. Since TRIP itself is exploratory, design elements may vary. And there are multiple outcomes..
TRIP has three arms: 1. The Recent infection network tracing (primary) arm; 2. the Contact tracing of HIV+' who are not recently infected comparison arm; and 3. the HIV negative comparison arm. Before the investigators start the main part of the intervention, and during the intervention as well, the investigators will use all available means to educate at-risk communities about the nature of acute and recent HIV infection and about the reasons not to stigmatize those who have recently been infected.
The Recent infection network tracing (primary) arm This is the primary arm of the intervention. It will include index subjects of two kinds: a. people who are tested and screened who turn out to have recent HIV infection (LAg+). b. People who are referred to us by clinicians as having recent or acute HIV infection. It will also include network/venue members of these index subjects. These will consist of 1. People who are in the social and/or risk networks of people who have recently become infected with HIV; and 2. People who go to their "venues"-i.e., places where people who have recently become infected with HIV say they sometimes go in order to engage in drug taking or sexual risk behaviors or to meet people with whom to take risks. Network tracing will recruit not only direct contacts of Index Cases but also the network/venue members of these contacts. (The investigators may continue to the third network ring if this seems warranted as part of the exploratory nature of the project).
Network/venue members will be tested for recent and acute HIV and perhaps for other diseases. Each time a network/venue member is found to have recent or acute HIV infection the investigators will then (for network/venue tracing purposes) treat them as if they were an index case in the sense that the investigators will trace their network/venue contacts.
Participants in the primary arm of the intervention who test HIV+ will all be referred for medical evaluation and treatment.
People who have recent or acute infection will receive expedited scheduling of doctor appointments and will receive direct assistance in getting to doctor's offices if they need it. They will also get extra assistance in receiving social assistance.
Whenever the investigators find an acute or recent infection, with their assistance the investigators will distribute oral and written "community alerts" that warn people in their networks and venues to be super-careful in their behaviors for the next 6 months because their social environment includes people who are highly infectious; that tells them how to be safer; and that repeats the importance of assisting rather than stigmatizing anyone they suspect has recently become infected.
- Contact tracing of HIV+ people who are not recently infected comparison arm This comparison arm will start with 50 subjects in each city who are HIV tested as part of the screening process and who are antibody positive but LAg negative-and who report that have just learned their HIV antibody status at this time. the investigators will recruit their sexual and injection partners, and other risk environment contacts, for two steps, as in Arm 1. If the investigators get a recent/acute in that set, the investigators will follow another two steps. (In analysis, the investigators will also study the subset of those the investigators would have recruited via more conventional contact tracing-i.e., those who would have been recruited if the investigators had stopped following the network whenever the investigators came to someone uninfected.) In each case, one key comparison will be the numbers of recents & acutes found in contact tracing vs. in the networks of recents. In addition, the investigators will compare this comparison group of non-recent HIV+ and their network members with the TRIP group of recently-infected people and their networks on behavior change and on adverse/supporting events.
- HIV negative comparison arm This comparison arm will consist of 150 uninfected people in each city whom the investigators screen in the course of testing. The key comparisons here are on two of the central variables: adverse/supportive events and behavior change. This comparison arm will help mitigate social desirability effects that can lead to inaccurate reporting and/or Hawthorne effects and related processes that can lead to behavior changes simply based on the interview. Participants in this arm will be matched on age (within five years), risk group, and gender with an Arm 1 member.
Assays by category of subject
Negative screenees (HIV-):
N=150 Baseline: They will have been tested for HIV antibodies by the Aristotle project (HIV-).
Follow up: They will be tested for HIV antibodies by the TRIP project. If HIV-, no more tests. If HIV+ confirmed by WB (seroconverters), they will also be tested using LAg and HIV RNA by TRIP.
If HIV+ confirmed by WB (seroconverters), the investigators presume they are recently infected (the investigators look for LAg and HIV RNA but this does not change how the investigators treat them. That is, the investigators treat them as seeds for finding more recents. However, analytically, it is possible that their first negative test was negative in error, so the investigators analyze this later).
Long-term positive screenees (HIV+, LAg-):
N=50 Baseline: They will have been tested at baseline for HIV antibodies (HIV+) by the Aristotle project and for LAg (they will be negatives-LAg-) by TRIP.
Follow-up: No test. HIV RNA data can be obtained by their clinical records, if available.
Contact tracing:
All traced contacts will be tested for HIV antibodies by TRIP. HIV positives (HIV+, confirmed by WB): They will be tested for LAg by TRIP. HIV positives (HIV+, confirmed by WB) who are also LAg positives (LAg+): They will be tested for HIV RNA by TRIP.
HIV positives (HIV+, confirmed by WB) who are LAg negatives (LAg-): No further test.
HIV negatives (HIV-): No further test (store in freezer for possible HIV RNA test in the future).
Follow-up of network/venue members of long-term positive screenees:
Long-term positives at baseline (HIV+ confirmed by WB, LAg-): HIV RNA info collection by clinical records.
Recently infected at baseline (HIV+ confirmed by WB, LAg+ and/or HIV RNA+): HIV RNA info collection by clinical records.
Negatives at baseline (HIV-): HIV test. If they are HIV positive (HIV+ confirmed by WB), then LAg test and HIV RNA by TRIP. If HIV-, the investigators stop.
If HIV+ confirmed by WB (seroconverters), the investigators presume they are recently infected (the investigators look for LAg and HIV RNA but this does not change how the investigators treat them. That is, the investigators treat them as seeds for finding more recents. However, analytically, it is possible that their first negative test was negative in error, so the investigators analyze this later).
Recently infected screenees (HIV+, LAg+):
N=unknown Baseline: They will have been tested at baseline for HIV antibodies by the Aristotle project (HIV+), for LAg (they will be positives-LAg+); and once known to be LAG+, they will be tested for HIV RNA (+) by TRIP.
Follow-up: HIV RNA by TRIP or collect info by clinical records. Then the investigators stop.
Network/venue members:
All will be tested for HIV antibodies by TRIP. HIV positives (HIV+ confirmed by WB): They will be tested for LAg by TRIP. HIV positives (HIV+ confirmed by WB) and LAg positives (LAg+): They will be tested for HIV RNA by TRIP.
HIV positives (HIV+ confirmed by WB) and LAg negatives (LAg-): No further test. HIV negatives (HIV-): They will be tested in pools using HIV RNA (batch testing) by TRIP.
Follow-up of network/venue members:
Long-term positives at baseline (HIV+ confirmed by WB, LAg-): HIV RNA info collection by clinical records.
Recently infected at baseline (HIV+ confirmed by WB, LAg+ and/or HIV RNA+): HIV RNA info collection by clinical records.
Negatives at baseline (HIV-, LAg-, HIV RNA-): HIV test. If they are HIV positive at follow-up (HIV+ confirmed by WB), then LAg test and HIV RNA by TRIP. If HIV-, the investigators stop.
If HIV+ confirmed by WB (seroconverters), the investigators presume they are recently infected (the investigators look for LAg and HIV RNA but this does not change how the investigators treat them. That is, the investigators treat them as seeds for finding more recents. However, analytically, it is possible that their first negative test was negative in error, so the investigators analyze this later).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Athens, Greece
- Hellenic Scientific Society for the Study of AIDS and STDs
-
-
-
-
-
Odessa, Ukraine, 65020
- International HIV/AIDS Alliance Ukraine
-
-
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- NORC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be able to answer questionnaire and qualify for one of the Arms
Exclusion Criteria:
- Inability to answer questionnaire
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Primary Recent infection network tracing
Subjects: LAg+ recent HIV infection testees & referrals with recent/acute infection; those in social/risk networks of index subjects; people who go to their venues.
We'll network trace direct contacts of Index Cases & network/venue members of contacts; and maybe 3rd ring as exploratory part of project.
We'll test network/venue members for recent & acute HIV.
If they have recent/acute HIV infection, their network/venue contacts will be traced.
We'll refer HIV+ Primary arm participants for medical/social evaluation and treatment; those with recent/acute infection on expedited scheduling and case management.
We will distribute "community alerts" to warn people in the social environments of recent/acute infectees to be super-careful in their behaviors for the next 6 months; to tell them how to be safer; and to repeat the importance of assisting rather than stigmatizing anyone they suspect has recently become infected.
|
May vary across sites
Other Names:
This will be expedited and assisted via community outreach for Recents and Acutes
Other Names:
This is described in Arms 1 and 2
Other Names:
When we find recently or acutely infected participants, we will issue community alerts as described in Arm descriptions
Throughout the study we will educate affected communities about recent and acute HIV infection and about the importance of avoiding stigma
As part of HIV testing, we will provide participants with standard counseling
|
Active Comparator: Contact tracing of long-term HIV+ people
We will start with 50 subjects in each city who test HIV+ but LAg negative-and who report they have just learned they are HIV+.
We will recruit their sexual and injection partners, and other risk environment contacts, for two steps, as in Primary Arm.
HIV+ will be referred for treatment; recent/acutes on expedited and assisted basis.
|
May vary across sites
Other Names:
This will be expedited and assisted via community outreach for Recents and Acutes
Other Names:
This is described in Arms 1 and 2
Other Names:
When we find recently or acutely infected participants, we will issue community alerts as described in Arm descriptions
Throughout the study we will educate affected communities about recent and acute HIV infection and about the importance of avoiding stigma
As part of HIV testing, we will provide participants with standard counseling
|
Active Comparator: HIV negative comparison arm
This comparison arm will consist of 150 uninfected people in each city whom we screen in the course of testing.
The key comparisons here are on two of the central variables: adverse/supportive events and behavior change.
This comparison arm will help mitigate social desirability effects that can lead to inaccurate reporting and/or Hawthorne effects and related processes that can lead to behavior changes simply based on the interview.
Participants in this arm will be matched on age (within five years), risk group, and gender with an Arm 1 member.
|
May vary across sites
Other Names:
When we find recently or acutely infected participants, we will issue community alerts as described in Arm descriptions
Throughout the study we will educate affected communities about recent and acute HIV infection and about the importance of avoiding stigma
As part of HIV testing, we will provide participants with standard counseling
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in estimated HIV transmission
Time Frame: The investigators will evaluate this 1, 2, 3 & 4 years after recruitment begins
|
Using phylogenetic techniques and network-based simulation modeling, teh investigators will analyze whether transmission of HIV got reduced in the city (or its key populations) as a whole.
Phylogenetic analysis is not limited to study participants.
|
The investigators will evaluate this 1, 2, 3 & 4 years after recruitment begins
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Numbers of people with recent and acute HIV infection enrolled into the study and then intervened with
Time Frame: The investigators will evaluate this 1 year, 2 years, 3 years and 4 years after recruitment starts
|
Comparison will be of numbers in the intervention group as compared with the numbers enrolled and intervened with in a comparison arm where index cases will be non-recent HIV positives.
This is a measure of our success in enrolling recently and acutely infected people; and then additional records over the duration of the study of how well we did in getting them into and keeping them into treatment.
|
The investigators will evaluate this 1 year, 2 years, 3 years and 4 years after recruitment starts
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Transmission behaviors among people with recent or acute HIV infection
Time Frame: from intake to intended-6 month follow up
|
This is an exploratory and developmental study, so the investigators will be using a range of risk behaviors and metrics on risk behaviors as outcome variables.
The behaviors include numbers of female and male partners of various categories, condom use with each category; use of drugs before or during sex; group sex behaviors; and a range of injection drug use behaviors and partnership characteristics for those who inject drugs.
|
from intake to intended-6 month follow up
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Samuel R Friedman, PhD, National Development and Research Institutes, Inc.
Publications and helpful links
General Publications
- Giallouros G, Pantavou K, Pampaka D, Pavlitina E, Piovani D, Bonovas S, Nikolopoulos GK. Drug Injection-Related and Sexual Behavior Changes in Drug Injecting Networks after the Transmission Reduction Intervention Project (TRIP): A Social Network-Based Study in Athens, Greece. Int J Environ Res Public Health. 2021 Mar 1;18(5):2388. doi: 10.3390/ijerph18052388.
- Smyrnov P, Williams LD, Korobchuk A, Sazonova Y, Nikolopoulos GK, Skaathun B, Morgan E, Schneider J, Vasylyeva TI, Friedman SR. Risk network approaches to locating undiagnosed HIV cases in Odessa, Ukraine. J Int AIDS Soc. 2018 Jan;21(1):e25040. doi: 10.1002/jia2.25040.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DP1DA034989 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States
Clinical Trials on Assays
-
University of California, San FranciscoHarvard Medical School (HMS and HSDM); National Institute of Allergy and Infectious... and other collaboratorsRecruitingTuberculosisSouth Africa, Uganda, Georgia, India, Philippines, Vietnam
-
Central Hospital, Nancy, FranceNot yet recruitingSARS-CoV-2 InfectionFrance
-
Fundación Española de Hematología y HemoterapíaRecruitingAcquired Thrombotic Thrombocytopenic PurpuraSpain, Portugal
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
Duke UniversityJohns Hopkins University; Memorial Sloan Kettering Cancer Center; Dana-Farber... and other collaboratorsCompletedProstate CancerUnited States
-
Petra Hartmann MD Ph.D.Not yet recruiting
-
University of California, San FranciscoJohns Hopkins University; University of California, Irvine; University Hospital... and other collaboratorsRecruitingTuberculosisZambia, Philippines, Nigeria
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingDuchenne Muscular DystrophyFrance
-
University of WashingtonNational Cancer Institute (NCI)CompletedChronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia... and other conditionsUnited States
-
St George's, University of LondonPublic Health EnglandRecruitingHIV/AIDS | Meningococcal DiseaseUnited Kingdom